Sinemet CR Related Published Studies
Well-designed clinical trials related to Sinemet CR (Carbidopa / Levodopa)
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release
carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a
phase 3 randomised, double-blind trial. [2013]
Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. [2010.12.15]
Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa. [2010.11]
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. [2009.07]
Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. [2007.11]
Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: Two double-blind, randomized, clinical trials. [2007.05.11]
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. [2005.05]
Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. [2004.01]
[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study] [2003.06]
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. [2000.05]
Occlusion and levodopa-carbidopa treatment for childhood amblyopia. [1998.10]
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. [1997]
Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. [1996.07]
International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. [1996.03]
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. [1995.02]
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. [1994.07]
A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. [1994.01]
Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa. [1992]
Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group. [1992]
Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR). [1991.08]
Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report. [1991.04]
Sinemet CR in Parkinson's disease. [1991.01]
Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. [1990]
Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. [1989.11]
Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. [1989]
Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. [1988.09]
Well-designed clinical trials possibly related to Sinemet CR (Carbidopa / Levodopa)
Double-blind study of the actively transported levodopa prodrug XP21279 in
Parkinson's disease. [2014]
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. [2011.06]
Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease. [2011.04]
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. [2010.05]
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. [2009.07]
Children show individual night-to-night variability of periodic limb movements in sleep. [2009.04.01]
Children show individual night-to-night variability of periodic limb movements in sleep. [2009.04]
Levodopa pharmacotherapy for cocaine dependence: Choosing the optimal behavioral therapy platform. [2008.04.01]
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. [2008.01]
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. [2007.09]
Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion. [2007.03]
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. [2004.10]
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. [2004.01]
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. [2003.05]
Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. [2002.03]
Endurance performance in humans: the effect of a dopamine precursor or a specific serotonin (5-HT2A/2C) antagonist. [1997.11]
Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism. [1996.06]
Controversies in the therapy of Parkinson's disease. [1996]
The effect of deprenyl and levodopa on the progression of Parkinson's disease. [1995.11]
Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. [1994.02]
Defining small differences in efficacy between anti-parkinsonian agents using gait analysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor. [1993.04]
Hereditary motor and sensory neuropathy with treatable extrapyramidal features. [1992.02]
Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients. [1992]
Comparative multiple-dose pharmacokinetics of controlled-release levodopa products. [1992]
The effect of dietary protein on the efficacy of L-dopa: a double-blind study. [1989.04]
Other research related to Sinemet CR (Carbidopa / Levodopa)
Population pharmacodynamics of IPX066: an oral extended-release capsule
formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in
patients with advanced Parkinson's disease. [2013]
Levodopa/carbidopa to improve motor function subsequent to brain tumor excision. [2013]
Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive
extended-release formulations in patients with Parkinson's disease. [2012]
Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. [2011.05]
Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. [2011]
Carbidopa/levodopa pharmacy errors in Parkinson's disease. [2010.12.15]
The place of L-dopa/carbidopa in persistent vegetative state. [2010.11]
Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa(R)) in Sweden. [2010]
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. [2008.12.03]
Acute overdose with controlled-release levodopa-carbidopa. [2008.03]
Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects. [2008]
Carbidopa/levodopa-responsive myoclonus. [2007.02.15]
The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing. [2006.07]
Other possibly related research studies
[Prevention and treatment of fluctuations in patients with Parkinson's disease] [2006.12.20]
Levodopa can worsen tremor associated with dystonia. [2006.10]
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. [2006.03]
[18F]FDOPA PET and clinical features in parkinsonism due to manganism. [2005.04]
Dopa-responsive dystonia presenting as delayed and awkward gait. [2008.04]
Interaction between levodopa and enteral nutrition. [2008.03]
Two cases of rapid onset Parkinson's syndrome following toxic ingestion of ethylene glycol and methanol. [2007.01]
Restless legs syndrome. [2008.07.15]
Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms. [2008.12.12]
Restless legs syndrome: diagnostic time-savers, Tx tips. [2009.08]
Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. [2009.04]
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. [2010.05]
Sildenafil induced choreoathetosis in men with Parkinson's disease. [2010.01]
Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. [2010.03]
[Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety] [2009.08]
The impact of levodopa on quality of life in patients with Parkinson disease. [2010.03]
Executive control in Parkinson's disease: effects of dopaminergic medication and deep brain stimulation on anti-cue keypress performance. [2011.08.15]
Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease. [2011.03]
Hemiparkinsonism-hemiatrophy syndrome. [2011.03]
Cutting the Gordian knot: the blockage of the jejunal tube, a rare complication of Duodopa infusion treatment. [2010.04]
Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. [2011.01]
Effect of S-COMT deficiency on behavior and extracellular brain dopamine concentrations in mice. [2010.09]
Levodopa-responsive parkinsonism after aneurysmal subarachnoid hemorrhage. [2010.10]
Improvement in drug-induced parkinsonism with electroconvulsive therapy. [2011.06]
Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. [2011.05]
Dynamic, adaptive changes in MAO-A binding after alterations in substrate
availability: an in vivo [(11)C]-harmine positron emission tomography study. [2012]
Determination of minimal clinically important change in early and advanced
Parkinson's disease. [2011]
Effect of controlled-release levodopa on the microstructure of sleep in
Parkinson's disease. [2011]
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to
L-dopa in the treatment of Parkinson's disease: a randomized, multicenter,
open-label, parallel-group study. [2010]
|